Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.
Angiogenesis plays an important role in the biology of hematological malignancies, including essential thrombocythemia (ET) and polycythemia vera (PV). Some data suggests that it has a role in the pathogenesis of thrombosis, the major clinical problem in ET and PV. The number of different subpopulations of circulating endothelial cells (CECs), plasma levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 and 2 (sVEGFR-1,2) and placenta growth factor (PlGF) were determined in 30 patients with ET and 16 patients with PV. Correlations between angiogenesis and JAK2-V617F mutational status, risk factors for thrombosis and coagulation activation markers were also assessed. The number of CEC subpopulations, were markedly higher in ET and PV patients, irrespective of JAK2-V617F status, when compared to the control group. The median values of activated CECs were markedly higher in PV patients with WBC >8.7 (x10(9)/l). Significantly higher VEGF plasma levels were found in ET patients and a similar trend was seen in PV patients in relation to healthy volunteers. The plasma levels of sVEGFR-1 were significantly higher, and PlGF levels markedly lower, in the ET and PV group than in controls. Our study also demonstrated markedly increased levels of D-dimer and TAT complexes in the patient groups. In conclusion, we found that angiogenesis, as measured by CEC numbers, is increased in ET and PV patients regardless of JAK2-V617F mutational status. Our results demonstrated that angiogenic cytokines interact with known thrombotic risk factors. We confirmed the coagulation activation in ET and PV patients but found no differences in levels of coagulation activation markers in relation to JAK2-V617F mutational status.
Treliński
Jacek
J
Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Ciolkowskiego 2, 93-510, Lodz, Poland. jtrel2001@yahoo.com
Wierzbowska
Agnieszka
A
Krawczyńska
Anna
A
Sakowicz
Agata
A
Pietrucha
Tadeusz
T
Smolewski
Piotr
P
Robak
Tadeusz
T
Chojnowski
Krzysztof
K
D000328:Adult; D000368:Aged; D001777:Blood Coagulation; D042783:Endothelial Cells / Q000473:pathology*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009389:Neovascularization, Pathologic / Q000097:blood; D000072483:Placenta Growth Factor; D011087:Polycythemia Vera / Q000097:blood* / Q000235:genetics; D011257:Pregnancy Proteins / Q000097:blood; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood
C000608036:PGF protein, human; D011257:Pregnancy Proteins; D042461:Vascular Endothelial Growth Factor A; D000072483:Placenta Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D053614:Janus Kinase 2
Leuk Res. 2009 Jan;33(1):67-73
18632151
Br J Haematol. 2009 Jul;146(2):150-7
19466975
J Biol Chem. 1994 Oct 14;269(41):25646-54
7929268
J Clin Invest. 2000 Jan;105(1):71-7
10619863
Eur J Haematol. 2005 Dec;75(6):492-7
16313261
Haematologica. 2009 Jul;94(7):911-8
19508974
Exp Hematol. 2009 Sep;37(9):1016-21
19559071
Pol Merkur Lekarski. 2006 Jun;20(120):717-20
17007278
Br J Haematol. 2008 Jan;140(2):162-8
18028479
J Mol Med (Berl). 1999 Jul;77(7):527-43
10494799
J Thromb Haemost. 2007 Apr;5(4):708-14
17263783
Haematologica. 2006 Feb;91(2):169-75
16461300
Blood. 2002 Jun 1;99(11):4131-7
12010817
Nat Med. 2001 May;7(5):575-83
11329059
Blood. 2005 Apr 15;105(8):3286-94
15618473
Leukemia. 2007 Sep;21(9):1952-9
17625606
Hematology. 2007 Dec;12(6):481-6
17852434
Haematologica. 2002 Jul;87(7):774-5
12091131
Blood. 2007 Mar 15;109(6):2310-3
17110452
Blood. 2000 Dec 15;96(13):4261-6
11110700
Lancet. 2005 Mar 19-25;365(9464):1054-61
15781101
Br J Cancer. 1998 Mar;77(6):956-64
9528841
Blood. 2001 Jun 1;97(11):3658-61
11369666
Leukemia. 2008 Jan;22(1):14-22
17882280
Leuk Lymphoma. 2009 Feb;50(2):247-53
19235016
Am J Hematol. 2002 Mar;69(3):159-63
11891801
Br J Haematol. 2005 Feb;128(3):275-90
15667529
Cancer Res. 2001 Jun 1;61(11):4341-4
11389057
Blood. 2006 Jul 15;108(2):452-9
16543470
Thromb Res. 2009 Sep;124(4):409-17
19299003
Leuk Lymphoma. 2005 Sep;46(9):1345-51
16109613
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62
11553814
Mayo Clin Proc. 2006 Feb;81(2):159-66
16471068
Ann Oncol. 2004 Jan;15(1):139-45
14679134
J Thromb Haemost. 2007 Aug;5(8):1679-85
17596137
Hematol Oncol. 2008 Dec;26(4):235-9
18504767
Blood. 2007 Aug 1;110(3):840-6
17379742
Leuk Lymphoma. 2009 Jan;50(1):62-7
19125384
Nat Med. 2003 Jun;9(6):669-76
12778165
Blood Coagul Fibrinolysis. 2009 Dec;20(8):646-51
19741509
Hematology. 2000;4(5):397-402
11399581
Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1757-60
10397695
Pathol Oncol Res. 2003;9(3):170-3
14530810
Exp Hematol. 2005 May;33(5):523-30
15850829
Cancer Res. 1999 Feb 1;59(3):728-33
9973224